China SXT Pharmaceuticals, Inc. SEC filings SXTC
China SXT Pharmaceuticals, Inc. has 169 filings in SEC EDGAR's recent list, going back to Dec 4, 2017. Its latest annual report, Form 20-F, was filed on Jul 1, 2026 for the period ended Mar 31, 2026. The most recent current report (Form 6-K) was filed on Oct 21, 2026. The company's fiscal year ends on March 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| SCHEDULE 13G | Ownership over 5% (passive) | Oct 15, 2026 | — |
| 3 | Initial insider ownership | Apr 27, 2026 | Jan 31, 2022 |
| 3 | Initial insider ownership | Apr 27, 2026 | Jul 4, 2017 |
| 3 | Initial insider ownership | Apr 27, 2026 | Jan 20, 2025 |
| 3 | Initial insider ownership | Apr 27, 2026 | May 22, 2021 |
| 3 | Initial insider ownership | Apr 27, 2026 | May 10, 2022 |
| 3 | Initial insider ownership | Apr 27, 2026 | Jan 20, 2025 |
| 3 | Initial insider ownership | Apr 27, 2026 | Dec 31, 2018 |
| SCHEDULE 13G | Ownership over 5% (passive) | Aug 7, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Aug 7, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Aug 7, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Aug 7, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Jan 21, 2025 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Oct 25, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Aug 15, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | May 31, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 9, 2024 | — |
| SC 13G | Ownership over 5% (passive) | Feb 9, 2024 | — |
| SC 13G | Ownership over 5% (passive) | Mar 29, 2023 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Mar 29, 2023 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 13, 2023 | — |
| SC 13D/A | Amended ownership over 5% (active) | Jan 30, 2023 | — |
| SC 13G | Ownership over 5% (passive) | Aug 25, 2022 | — |
| SC 13G | Ownership over 5% (passive) | Jan 21, 2022 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 16, 2021 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 11, 2021 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 14, 2020 | — |
| SC 13G | Ownership over 5% (passive) | Feb 7, 2020 | — |
| SC 13G | Ownership over 5% (passive) | May 8, 2019 | — |
| SC 13D | Ownership over 5% (active) | Feb 15, 2019 | — |
Showing 30 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- SXTC (Nasdaq)
- Fiscal year ends
- March 31
- Incorporated in
- Virgin Islands, British
- Headquarters
- Taizhou
- SEC filer status
- Non-accelerated filer
- SEC CIK
- 1723980
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.